Image Name - Referrals for Clinicians

How We Work With Healthcare Providers

How We Work With Healthcare Providers

In our experience, patients are best served when the all members of the provider team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

Submit your referral
Image Name - Referrals for Clinicians

We Work With:

  • Psychiatrists
  • Therapists
  • Psychologists
  • Neurologists
  • Pain Specialists
  • Primary Care Physicians
  • Coaches
  • Social Workers

Treatments for:

  • Depression
  • Anxiety
  • PTSD
  • Migraines & Headaches
  • CRPS & Chronic Pain
  • Immunity & Resilience

Our Services:

  • IV Ketamine
  • Spravato (intranasal Ketamine)
  • Stellate Ganglion Blocks (SGB)
  • IV Nutrients & Vitamins
  • IV NAD+
  • IV Glutathione
  • Ketamine Assisted Psychotherapy (KAP)
  • Life Skills Coaching

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

Research Papers

Ketamine treatment for refractory anxiety: A systematic review

May 4, 2022

Jamie L. Tully, Amelia D. Dahlén, Connor J. Haggarty, Helgi B. Schiöth, Samantha Brooks First […] Read More

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder

April 14, 2022

C. Sophia Albott, Kelvin O. Lim, Christopher Erbes, Paul Thuras, Joseph Wels, Susanna J.Tye, Paulo […] Read More

The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis

March 9, 2022

Rui Du, Ruili Han, Kun Niu, Jiaqiao Xu, Zihou Zhao, Guofang Lu and Yulong Shang […] Read More

Ketamine for Adolescent Suicidality

January 28, 2022

In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.

Read More

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

January 19, 2022

Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young-McCaughan, Paulo R. […] Read More

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

December 15, 2021

Elizabeth Whittaker, Alisher R. Dadabayev, Sonalee A. Joshi, Paul Glue Published 15 December 2021| https://doi.org/10.1177/20451253211056743 […] Read More

Trial of Psilocybin versus Escitalopram for Depression

April 15, 2021

Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.

Read More

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

March 17, 2021

Roger S. McIntyre, M.D., Joshua D. Rosenblat, M.D., M.Sc., Charles B. Nemeroff, M.D., Ph.D., Gerard […] Read More

Scroll to Top